Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients

NeuroImage
J BlinE C Laterre

Abstract

Cerebral blood flow (CBF) and glucose consumption (GC) are both tracers of brain metabolic activity used to image the human brain in vivo. To know if both tracers reacted in the same manner when brain cholinergic neurotransmission was activated, CBF and GC were measured in young normals (YN), aged normals (AN), and Alzheimer's Disease patients (AD) using positron emission tomography (PET), H2 15O, and 18F-FDG. Each subject was studied twice, under placebo and physostigmine, in randomized order and blind fashion using the maximal tolerated dose of physostigmine individually determined. Under physostigmine CBF increased significantly (P = 0.0007) in posterior regions of the cerebral cortex and in the subcortical structures. Inversely, GC was decreased significantly in most regions. The largest decrease was seen in the prefrontal region of the cerebral cortex (P < 0.0001). Significant regional decreases were registered in all three groups of subjects, but were larger in AD than in controls. Looking at the absolute values of prefrontal cortex metabolism we found no correlation (r = 0.04) between the responses of CBF and GC. After normalization of the regional values for the mean we found a significant positive correlation between t...Continue Reading

Citations

Apr 16, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bryon AdinoffMunro Cullum
Aug 29, 2014·Frontiers in Pharmacology·Gustavo C RománRonald E Fisher
Jan 22, 2004·Seminars in Nuclear Medicine·Satoshi MinoshimaDavid E Kuhl
Dec 11, 1999·Journal of Geriatric Psychiatry and Neurology·C C Meltzer
Dec 12, 2017·Journal of Alzheimer's Disease : JAD·Rachel HarrisSeth Love
Aug 6, 1999·Journal of Clinical Pharmacology·M E Schmidt
Apr 13, 1999·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·G MehlhornR Schliebs
Jun 22, 2016·Brain Pathology·Seth Love, J Scott Miners
Mar 29, 2006·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Jurgen A H R Claassen, René W M M Jansen
Jan 1, 2007·Dementia & Neuropsychologia·Eliasz EngelhardtJerson Laks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.